[ Back to EurekAlert! ] Public release date: 7-Dec-2012
[ | E-mail Share Share ]

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center

John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting

Nearly one-third of the studies will be presented orally at this premier hematology research conference

Hackensack, N.J. (December 6, 2012) – Remaining at the forefront of blood cancer research, John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 37 blood cancer studies at the 2012 American Society of Hematology (ASH) Annual Meeting being held in Atlanta from December 8-11.

"The research we are presenting at this year's ASH annual meeting underscores our commitment to bring patients access to promising novel therapies," said Andre Goy, M.D., M.S., who is chairman and director and chief of lymphoma, John Theurer Cancer Center and a Physician member of Regional Cancer Care Associates. "It is an exciting time in oncology given the expanding panoply of new medicines that are currently in development, many of which are taken orally, with less side effects and offering new possibilities to improve our patients quality of life and outcome."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. Nearly one-third of the presentations showcased at the ASH annual meeting by John Theurer Cancer Center have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, and multi-center and international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic and MD Anderson.

"John Theurer Cancer Center's early drug discovery program is part of many of the exciting developments at this year's ASH, including second generation proteasome inhibitors, such as oprozomib and lenalidomide, and other emerging agents, such as selective kinase inhibitor GS-1101, BTK inhibitor ibrutinib, and SYK inhibitor fostamatinib," said Dr. Goy.

The research presented by Regional Cancer Care Associates physicians at John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia. Regional Cancer Care Associates physicians at John Theurer Cancer Center are lead or senior author in 15 studies, including Andre Goy, M.D.; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Tatyana Feldman, M.D., lymphoma oncologist; Stuart Goldberg, M.D., chief, leukemia; Robert Korngold, Ph.D., chief, research; Anthony Mato, M.D., director of our chronic lymphocytic leukemia program; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma.

"We are committed to contributing to blood cancer research through our own investigator-initiated research and collaborating with other institutions," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center and President of Regional Cancer Care Associates. "I want to thank our physicians and research staff for their dedication, as well as all of the patients who participate in our studies."

For those attending the ASH annual meeting, visit John Theurer Cancer Center at Booth 3413. The following are abstracts and presentations at ASH annual meeting from John Theurer Cancer Center. For ongoing updates and complete list of abstracts, please visit jtcancercenter.org/ash2012.

John Theurer Cancer Center 2012 ASH Abstracts:

Lymphoma

Multiple Myeloma

Stem Cell Transplantation

Leukemia

Hematologic Malignancies

###

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University is among the nation's top 50 U.S. News and World Report Best Hospitals for cancer – the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertise—all under one roof. Physicians at the John Theurer Cancer Center are members of Regional Cancer Care Associates one of the nation's largest professional hematology/oncology groups. For more information please visit jtcancercenter.org.

Media Contact:

Amy Leahing
305.458.0599
aleahing@p4strategy.com



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.